Related Experiment Videos
Cardiopulmonary bypass in humans: bypassing unfractionated heparin
1Department of Surgery, Northwestern University Medical School, Chicago, Illinois 60611, USA. jwf@nwu.edu
Insights
Unfractionated heparin is the preferred anticoagulant for cardiopulmonary bypass (CPB). Alternative anticoagulants lack standard dosing, monitoring, and antidotes, limiting their use in CPB procedures.
Area of Science:
- Cardiovascular Surgery
- Anesthesiology
- Hematology
Background:
- Cardiopulmonary bypass (CPB) requires effective anticoagulation.
- Heparin-induced thrombocytopenia (HIT) necessitates alternative anticoagulants during CPB.
- Current alternatives include seven anticoagulants beyond unfractionated heparin.
Purpose of the Study:
- To review the current landscape of alternative anticoagulants used during CPB.
- To evaluate the challenges and limitations associated with these alternative anticoagulants.
- To determine the current gold standard for anticoagulation in CPB.
Main Methods:
- Review of collective clinical experience with alternative anticoagulants in CPB.
- Analysis of current practices and challenges in CPB anticoagulation.
- Comparison of alternative anticoagulants against unfractionated heparin.
Main Results:
- Seven anticoagulants have been used as alternatives to unfractionated heparin in CPB.
- These alternatives are primarily used in patients with heparin-induced thrombocytopenia.
- Significant limitations exist for all alternative anticoagulants, including lack of standard dosing, reliable monitoring, and proven antidotes.
Conclusions:
- Unfractionated heparin remains the anticoagulant of choice for standard CPB.
- Alternative anticoagulants for CPB lack the necessary standardization and safety measures for widespread adoption.
- Further research is needed to develop reliable and safe alternative anticoagulation strategies for CPB.
Abstract:
Seven anticoagulants besides unfractionated heparin have been used for human cardiopulmonary bypass (CPB), mainly in patients with heparin-induced thrombocytopenia. The collective experience with these alternative anticoagulants provides a perspective on current efforts aimed at improving CPB anticoagulation. Unfortunately, each alternative currently lacks a standard dosing schedule and a reliable method of monitoring the adequacy of its anticoagulant effect during CPB. Most also lack proven antidotes. Thus, unfractionated heparin remains the anticoagulant of choice for standard CPB.